Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00251901 |
The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.
Condition | Intervention | Phase |
---|---|---|
Chest Pain Gastroesophageal Reflux |
Drug: Esomeprazole |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomized Double-Blind Placebo-Controlled Multi-Centre Pilot Study to Assess Symptom Response in Subjects With Pain or Discomfort in the Chest Receiving Oral Treatment With Esomeprazole 40 Mg Bid for 4 Weeks. |
Estimated Enrollment: | 600 |
Study Start Date: | May 2004 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | AstraZeneca Nexium Medical Sciences Director, MD | AstraZeneca |
Study ID Numbers: | D9914C00001 |
Study First Received: | November 9, 2005 |
Last Updated: | November 9, 2005 |
ClinicalTrials.gov Identifier: | NCT00251901 |
Health Authority: | Canada: Health Canada |
Gastroesophageal reflux disease GERD |
Deglutition Disorders Esophageal Motility Disorders Signs and Symptoms Digestive System Diseases Esophageal disorder Gastrointestinal Diseases |
Omeprazole Pain Esophageal Diseases Gastroesophageal Reflux Chest Pain |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |